Valneva SE reported positive antibody persistence data on September 30, 2025, four years after vaccination with a single dose of its chikungunya vaccine, IXCHIQ®. The results confirmed strong and long-lasting antibody persistence across all age groups investigated, aligning with the company's expectations.
Among 254 healthy adults still followed in the trial, 95% maintained neutralizing antibody titers well above the seroresponse threshold four years after the single-dose vaccination. The persistence of antibodies in older adults (age 65+) was comparable to that in younger adults (18-64 years of age) in terms of geometric mean titers and seroresponse rates.
These four-year data further reinforce IXCHIQ®'s unique profile and its ability to generate a robust, durable antibody response with just a single dose. This long-term protection is highly valuable for travelers, residents in endemic areas, or those facing outbreak situations, particularly in low- and middle-income countries where vaccine access is often limited.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.